Sustained Release Ocular Bevacizumab for the treatment of wet acute macular degeneration

Información del proyecto

STROBE

Identificador del acuerdo de subvención: 672768

DOI 10.3030/672768

Proyecto cerrado

Fecha de la firma de la CE 10 Abril 2015

Fecha de inicio 1 Mayo 2015

Fecha de finalización 31 Octubre 2015

Financiado con arreglo a

• INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies

Coste total € 71 429,00

Aportación de la UE € 50 000,00

Coordinado por

CRITICAL PHARMACEUTICALS LIMITED
United Kingdom

Objetivo

Sustained Release Ocular Bevacizumab for the treatment of wet acute macular degeneration

This feasibility study is to verify the technical and economic viability of a sustained release bevacizumab product (SR Bevacizumab) to improve the safety, cost-effectiveness and patient acceptability for the treatment of wet age-related macular degeneration (AMD). AMD is the leading cause of blindness in those aged over 50 and causes blurring, distortion and loss of central vision and almost always affects quality of life. Prototype SR Bevacizumab products will be manufactured using CriticalMix, an advanced manufacturing and processing technology developed by Critical Pharmaceuticals, which will encapsulate bevacizumab in biodegradable polymers suitable for sustained release of the drug in the eye.

Ámbito científico

• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs
• natural sciences › chemical sciences › polymer sciences
• medical and health sciences › clinical medicine › ophthalmology
• medical and health sciences › medical biotechnology › cells technologies › stem cells

Programa(s)

• H2020-EU.2.1.2. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies Main Programme
• H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument

Tema(s)

• NMP-25-2014-1 - Accelerating the uptake of nanotechnologies, advanced materials or advanced manufacturing and processing technologies by SMEs

Convocatoria de propuestas

H2020-SMEInst-2014-2015

Consulte otros proyectos de esta convocatoria

Convocatoria de subcontratación

H2020-SMEINST-1-2014

Régimen de financiación

SME-1 - SME instrument phase 1

Coordinador

CRITICAL PHARMACEUTICALS LIMITED

• Aportación neta de la UEn: € 50 000,00
• Dirección: BIOCITY NOTTINGHAM - PENNYFOOT STREET ; NG1 1GF NOTTINGHAM ; Reino Unido
• Pyme Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención. Sí:
  Región
  East Midlands (England) › Derbyshire and Nottinghamshire › Nottingham
• Región: East Midlands (England) › Derbyshire and Nottinghamshire › Nottingham
• Tipo de actividad: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Coste total: € 71 429,00